Clinical Evaluation of Proclear Monthly and Avaira Vitality
Phase: NA
Conditions: Myopia, Hyperopia
Sponsor: CooperVision, Inc.

Confidential 
EX-MKTG-142 Clinical Evaluation of Proclear Monthly and Avaira Vitality  
1 
 
 
 
 
Clinical Evaluation of Proclear Monthly and Avaira Vitality 
 
 
 
Sponsor Study Code: 
EX-MKTG-142 
Protocol Date: 
July 10, 2022 
Sponsor Company:  
CooperVision, Inc. 
Document Type: 
Protocol 
Study Category: 
 
Post Market  
Start Date: 
Finish Date: 
Clinical Site: 
September  2022 
October 2022 
Clinic of Optometry, Faculty of Optics and 
Optometry; Universidad Complutense de 
Madrid  
Revision History 
Document number 
Date 
Comments 
EX-MKTG-142 
07/10/2022 
First draft (v 1.0)  
EX-MKTG-142 
07/11/2022 
Second Draft (v 2.0) 
EX-MKTG-142 
07/11/2022 
FINAL (v 3.0) 
 
 

Confidential 
EX-MKTG-142 Clinical Evaluation of Proclear Monthly and Avaira Vitality  
2 
 
 
 
 
 
 
 

Confidential 
EX-MKTG-142 Clinical Evaluation of Proclear Monthly and Avaira Vitality  
4 
Table of Contents 
1 Introduction 
.............................................................................................................................. 6 
2 Study Objective 
........................................................................................................................ 6 
3 Study Hypothesis 
..................................................................................................................... 6 
3.1 
Study Hypothesis 
................................................................................................................ 6 
4 Study Design 
............................................................................................................................ 7 
5 Investigational Sites 
................................................................................................................. 7 
5.1 
Number of Sites 
.................................................................................................................. 7 
5.2 
Investigator Recruitment 
..................................................................................................... 7 
6 Ethics Review / Statement of Compliance 
.............................................................................. 7 
6.1 
Relevant Standards / Guidelines ........................................................................................ 7 
6.2 
Institutional Review Board .................................................................................................. 7 
6.3 
Clinical Trial Registration 
.................................................................................................... 8 
6.4 
Informed Consent 
............................................................................................................... 8 
7 Potential Risks and Benefits to Human Subjects .................................................................. 8 
8 Materials and Methods 
............................................................................................................. 9 
8.1 
Participants 
......................................................................................................................... 9 
Inclusion criteria ......................................................................................................................... 9 
8.2 
Study Materials 
................................................................................................................. 
10 
8.2.1 Contact lens 
................................................................................................................ 
10 
8.2.2 Contact Lens care 
....................................................................................................... 
10 
8.2.3 Storage of Study Medications/Treatments .................................................................. 
11 
8.2.4 Clinical Supply Inventory 
............................................................................................. 
11 
8.2.5 Disposal of Consumables ........................................................................................... 
11 
8.2.6 Masking and Control of Study Materials 
...................................................................... 
11 
8.2.7 Ordering and Accountability of Study Materials 
........................................................... 
11 
8.3 
Visit Schedule and Procedures 
......................................................................................... 
11 
 

Confidential 
EX-MKTG-142 Clinical Evaluation of Proclear Monthly and Avaira Vitality  
5 
8.3.1 Visit 1: Baseline / Trial Fit / Lens order 
........................................................................ 
11 
8.3.2 Visit 2: Lens dispensing (Fit LENS A / Evaluate) 
......................................................... 
12 
8.3.3 Visit 3: 15 minutes (Evaluate LENS A / Fit LENS B).................................................... 
12 
8.3.4 Visit 3: Lens dispensing (Fit LENS B / Evaluate) 
......................................................... 
12 
8.3.5 Visit 4: 15 minutes (Evaluate LENS B / Study Exit) 
..................................................... 
13 
9 Adverse Event Reporting 
....................................................................................................... 
13 
9.1 
Adverse Response Definitions 
.......................................................................................... 
13 
9.2 
Procedures for Adverse Events ........................................................................................ 
15 
9.3 
Reporting Adverse Events 
................................................................................................ 
15 
9.4 
Discontinuation from the Study 
......................................................................................... 
16 
10 Statistical Analysis 
................................................................................................................. 
16 
10.1 Statistical analysis ............................................................................................................ 
16 
10.2 Sample size 
...................................................................................................................... 
16 
11 Data Quality Assurance 
......................................................................................................... 
17 
11.1 Study monitoring 
............................................................................................................... 
17 
11.2 Record keeping ................................................................................................................ 
17 
11.3 Record retention 
............................................................................................................... 
18 
11.4 Data Entry / Data Management ........................................................................................ 
18 
11.5 Confidentiality 
................................................................................................................... 
18 
 
 
 
 
 
 
 

Confidential 
EX-MKTG-142 Clinical Evaluation of Proclear Monthly and Avaira Vitality  
6 
1 Introduction 
Silicone hydrogel materials make up the majority of contact lens fits, and refits as recently reported 
(Contact Lens Spectrum market data).  1 In the United States, for 2021, silicone hydrogels were 
reported in usage at 69%, while hydrogels were reportedly used in 20% of fits in 2021. Data from 
Contact Lens Spectrum’s market research indicates that across all contact lens designs, most of the 
reported fits and refits were with soft spherical lenses (48% versus 52% in 2020).
1 Soft contact lenses, 
(SCLs), are a great option for new and established contact lens wearers, offering good vision 
performance with the added benefit of improved cosmesis and convenience compared to spectacles, 
and provide them the flexibility to change-up their vision correction. 
CL manufacturers are continually innovating in this area, with the increased availability of SCLs with 
novel designs in a range of replacement frequencies, and different materials including silicone 
hydrogels. Therefore, CooperVision is interested in comparing the short-term clinical performance and 
subjective acceptance of Proclear Monthly, (LENS A), hydrophilic soft contact lens, to the  Avaira 
Vitality, (LENS B), silicone hydrogel contact lens. A non-dispensing fitting study is proposed to 
evaluate the short-term clinical performance of these lenses. 
2 Study Objective   
The aim of this non-dispensing fitting study is to evaluate the short term lens fit, vision performance 
and patient subjective experiences of the Proclear Monthly when compared to the Avaira Vitality after 
15 minutes of daily wear each.  
The primary outcome variable is: 
• Lens Fit Acceptance Ratings (assessed by investigator)  
 
 
 
 
  
 
 
 
 
 
 
 
 
3 Study Hypothesis   
3.1  Study Hypothesis  
 
• Null hypothesis (Ho): There is no difference in clinical performance and subjective 
assessments between soft contact lens types. 
• Alternative hypothesis (H1): There is a difference in clinical performance and subjective 
assessments between soft contact lens types. 

Confidential 
EX-MKTG-142 Clinical Evaluation of Proclear Monthly and Avaira Vitality  
7 
4 Study Design  
This is a 40-subject, single-blind, (participant masked), interventional, prospective, direct refit, bilateral 
wear study.  It is anticipated that this study will involve 4 visits as follows: V1: (BL/trial fit/lens order), 
V2: Dispense / evaluate P1. V3: 15 minutes. Evaluate P1/Dispense P2. V4: 15 minutes. Evaluate P2 
/ study exit. 
5 Investigational Sites 
5.1  Number of Sites 
This will be a single center investigational site in Madrid (Spain). (Target 40 subjects).   
5.2  Investigator Recruitment  
This study will be conducted at School of Optometry Clinic; at the University Complutense of Madrid 
(Spain). The Investigators will be required to fulfil the following criteria: 
• 
Licensed optometrist with at least two years of contact lens fitting experience. 
• 
Experienced Investigators who will be trained in Good Clinical Practice (GCP) by the 
principal investigator. 
• 
In-office email or fax. 
• 
Willingness to follow the study protocol and to co-operate with the study monitors. 
 
This clinical study is designed to be in conformance with the ethical principles in the Declaration of 
Helsinki, with the ICH guidelines for Good Clinical Practice (GCP) and all the applicable local 
guidelines.  
6 Ethics Review / Statement of Compliance 
6.1  Relevant Standards / Guidelines 
This implementation document has been developed in accordance with the following:   
• ISO 14155. Clinical Investigation of Medical Devices 
• ICH Harmonized Tripartite Guideline for Good Clinical Practice 
• Declaration of Helsinki 
6.2  Institutional Review Board 
This study will be conducted in accordance with Institutional Review Board regulations (U.S. 21CFR 
Part 56.103) or applicable IEC regulations. Copies of all IRB/IEC correspondence with the 
investigator/sponsor will be kept on file. The study will commence upon approval from the following 

Confidential 
EX-MKTG-142 Clinical Evaluation of Proclear Monthly and Avaira Vitality  
8 
Institutional Review Board: Hospital Clínico San Carlos Profesor Martín Lagos, s/n. - Puerta G - 4ª 
Norte Madrid 28040 Madrid España. Tel. 91 330 34 13. Email. ceic.hcsc@salud.madrid.org. 
 
6.3  Clinical Trial Registration 
This study will be registered with clinical trials.gov in accordance with section 801 of the Food and 
Drug Administration (FDA) Act which mandates the registration of certain clinical trials of drugs and 
medical devices. 
6.4  Informed Consent 
Informed consent, (Appendix 1), shall be obtained in writing from the subject and the process shall be 
documented before any procedure specific to the clinical investigation is carried out. 
7 Potential Risks and Benefits to Human Subjects 
There may be direct benefits to the subjects in this study such as improved vision, comfort, 
convenience, and cosmetic advantage.   Participation in a study may contribute to scientific research 
information that may be used in the development of new contact lens products. In addition, subjects 
will receive an examination of the front part of their eyes and may have the opportunity to try a different 
type of soft contact lenses and/or different lens care products at no cost to them. The contact lens 
materials used in this study are commercially available intended for daily wear (NOT extended wear) 
similar to the average wearing time of 10-16 hours for daily wear lenses.  
This study is considered to be a non-significant risk study based on United State Food and Drug 
administration (FDA) and International Standards Organization (ISO) guidelines because the study 
devices used as intended in this study (daily wear) don’t represent a potential for serious risk to the 
health, safety or welfare of the subject, and (2) it is not an implant, (3) it is not used to support or 
sustain human life, (4) it is not of substantial importance in diagnosing, curing, mitigating or treating 
disease or otherwise prevents impairment of human health, (5) does not present a potential for serious 
risk to the health, safety or welfare of the subject.   
Complications that may occur during the wearing of contact lenses include discomfort, dryness, aching 
or itching eyes, excessive tearing, discharge, hyperemia and variable or blurred vision.  More serious 
risks may include photophobia, iritis, corneal edema or eye infection. Although contact lens-related 
infections are very infrequent, the possibility does exist.  The incidence of infection due to day-wear 
soft lenses is 0.035%. Almost always an infection will occur only in one eye.  This risk is assumed by 
35-million Americans who currently wear contact lenses. Routine clinical procedures including auto-
refraction, auto-keratometry, visual acuity, anterior ocular health assessment, and contact lens fitting 
will be used. In addition, high magnification imaging of the lens fit may be made using 35 mm or digital 
cameras, in vivo confocal microscopy, and/or specular microscopy. Patients will be monitored in the 
clinic during the study to reduce if not eliminate the occurrence of adverse or potential adverse events. 
Patients will be given instructions from the study investigator regarding early symptoms and signs of 
adverse events and their contact information.  

Confidential 
EX-MKTG-142 Clinical Evaluation of Proclear Monthly and Avaira Vitality  
9 
8 Materials and Methods 
8.1  Participants 
Habitual soft contact lens wearers who currently wear sphere contact lenses for distance correction, 
that provide written informed consent and meet the protocol entrance criteria. Subjects will be recruited 
from the University Complutense School of Optometry databases who agree to voluntarily participate 
in the study (Appendix 2, timeline).  All subjects will be screened to determine study eligibility. Each 
subject will be given a unique ID number. Additionally, all subjects must meet the study inclusion and 
exclusion criteria listed below.  
Inclusion criteria 
A person is eligible for inclusion in the study if he/she: 
1  Is at least 18 years of age and has full legal capacity to volunteer. 
2. Has read and signed an information consent letter. 
3. Self-reports having a full eye examination in the previous two years. 
4. Anticipates being able to wear the study lenses for at least 8 hours a day, 5 days a week. 
5. Is willing and able to follow instructions and maintain the appointment schedule. 
6. Habitual soft contact lens wearers who currently wear sphere contact lenses, or use spectacles for 
all distances vision correction, for the past 3 months minimum. 
7. Has refractive astigmatism no higher than -0.75DC. 
8. Can be fit and achieve binocular distance vision of at least 20/30 Snellen (or +0.20 
logMAR) which participants also deem to be ‘acceptable’, with the available study lens 
parameters (powers +8.00 to -12.00DS) (see Table 1). 
Exclusion Criteria 
A person will be excluded from the study if he/she: 
1. Is participating in any concurrent clinical or research study. 
2. Has any known active* ocular disease and/or infection that contraindicates contact lens wear. 
3. Has a systemic condition that in the opinion of the investigator may affect a study outcome variable. 
4. Is using any systemic or topical medications that in the opinion of the investigator may affect contact 
lens wear or a study outcome variable. 
5. Has known sensitivity to the diagnostic sodium fluorescein used in the study. 
6. Self-reports as pregnant, lactating or planning a pregnancy at the time of enrolment. 
7. Has undergone refractive error surgery or intraocular surgery. 
 
* For the purposes of this study, active ocular disease is defined as infection or inflammation which 
requires therapeutic treatment. Mild (i.e., not considered clinically relevant) lid abnormalities 

Confidential 
EX-MKTG-142 Clinical Evaluation of Proclear Monthly and Avaira Vitality  
11 
8.2.3 Storage of Study Medications/Treatments  
There are no unapproved investigational products used in this study requiring special storage 
accommodations.  
8.2.4 Clinical Supply Inventory 
There are no unapproved investigational products used in this study requiring special inventory 
requirements.  
8.2.5 Disposal of Consumables 
This study dispenses consumables (lenses) to participants for use during the study. Study lenses worn 
by participants will be discarded by the principal investigator at the end of the study.  
8.2.6 Masking and Control of Study Materials 
The contact lenses, (LENS A, and LENS B), will be masked to the subject only. The lenses will be 
removed from their blister pack by an assistant and transferred to an unmarked lens case to maintain 
the participants masked of the study lenses. Participants will then be instructed to remove the lenses 
from the lens case and insert them onto their eyes. It is not possible for the study investigators to be 
masked because of the need to follow the specific lens fitting guide during the lens prescription 
optimization visit.     
 
8.2.7 Ordering and Accountability of Study Materials 
The study sponsor will supply the investigators with the study lenses to use during the study.  
8.3 Visit Schedule and Procedures 
This will be an interventional, subject masked, bilateral, non-dispensing fitting study.  Participants will 
be examined at two different points over the course of one day, V1 (lens dispensing), V2 (15 minutes 
post lens settling).  Participants will wear two different pairs of lenses with LENS A fitted first to all 
participants, followed by LENS B. Anterior ocular health examination will be performed at baseline 
without the use of fluorescein*.  
* Fluorescein will not be used before lens dispensing to prevent potential eye discomfort that could influence subjective 
comfort ratings after lens fitting and settling. However, fluorescein will be instilled at the last visit upon lens removal. 
The following outline identifies the two study visits and the general procedures, (Appendix 5), to be 
conducted at each visit for each day of the study and recorded in the case report forms (Appendix 6): 
8.3.1 Visit 1: Baseline / Trial Fit / Lens order 
• Explanation of the study. 
• Sign informed consent form.  
• 
 
• Insert trial LENS A  
• 
 
•  Evaluate lens fit (centration, post blink movement, lens fit acceptance) 
• 
 

Confidential 
EX-MKTG-142 Clinical Evaluation of Proclear Monthly and Avaira Vitality  
16 
within 24 hours of the investigator becoming aware of the event. The Principal Investigator will report 
the event to the EC/IRB as soon as possible (by fax, mail/delivery, phone, or email), but within 10 
business days of becoming aware of the problem.  All fatal or life threatening events will be reported 
immediately to the IRB. 
 
Significant and Non-Significant Adverse Events will be reported to the sponsor as soon as 
possible, but no later than 5 working days after the occurrence. 
Sponsor contact details are: 
   
 
 
    
 
 
  
 
 
   
 
 
 
 
9.4    Discontinuation from the Study  
All discontinuations will be fully documented on the appropriate CRF Exit and Adverse Event forms as 
needed.  Participants will be followed until resolution (in most instances) and are free of the ophthalmic 
insert related complications or other ocular pathology. When possible study lenses involved in an 
Adverse Event will be returned to the sponsor in a new tightly sealed contact lens case and labeled 
with the subject identification and stored in Unisol non-preserved saline. 
10 Statistical Analysis  
10.1 Statistical analysis 
Summary statistics will be produced,  
(e.g., mean, standard deviation), by the principal investigator 
(GIO). Differences between lenses will be compared using Paired t-tests. Paired t-tests /analysis of 
variance for normal (interval/continuous) data, Wilcoxon’s signed ranks test for non-normal (ordinal) 
data, chi-squares test for nominal data. A Chi-Square test will be used to evaluate lens preference 
questions. All participants who are evaluated in the study will be used in the analysis. In the event of 
missing data individual number of points will be excluded in the analysis and not extrapolated from the 
collected data. The critical alpha level for statistical significance will be set at p ≤ 0.05, with adjustment 
for multiple comparisons. 
10.2 Sample size 
The sample size was calculated using data of investigator’s lens fit acceptance collected in a previous 
study that evaluated soft contact lenses (CooperVision, data on file). Figure 1 shows the sample size 
determination for a paired t-test, (alpha=0.05), in order to detect a difference in mean lens fit 
acceptance scores between lenses. Assuming a standard deviation of 0.65, a sample size of 39 
completed subjects provides 80% power to detect a difference of 0.35 points on a 0 - 5 scale in fit 
acceptance ratings. The study will aim to complete 40 subjects in total. 
 

Confidential 
EX-MKTG-142 Clinical Evaluation of Proclear Monthly and Avaira Vitality  
17 
 
 
 
 
 
 
 
 
11 Data Quality Assurance 
11.1  Study monitoring 
A site visit or discussion may be conducted during the course of the study as appropriate. Prior to final 
data freeze, a close-out visit/discussion may be warranted to check for accuracy and completeness of 
records. The sponsor or sponsor’s representatives will be authorized to gain access to the source 
documentation for the purposes of monitoring and auditing the study. 
 
11.2 Record keeping 
Detailed records of all study visits will be made using the electronic Case Report Forms (CRFs).  

Confidential 
EX-MKTG-142 Clinical Evaluation of Proclear Monthly and Avaira Vitality  
18 
 
11.3 Record retention 
Following study completion, data will be available in electronic and/or paper format for audit, sponsor 
use, or subsequent analysis. The original clinical raw data (including completed CRFs and Informed 
Consent forms) will be retained according to guidelines set forth in the general work agreement with 
the site. The Sponsor will be notified and consulted if ever the files are to be destroyed.  In the event 
that this implementation document is indicated for design verification and validation purposes, as 
indicated on the title page, all original raw data forms and completed CRF’s will be forwarded to the 
sponsor at completion of the final report. 
11.4 Data Entry / Data Management 
Data will be entered into an electronic spreadsheet. Study staff will only be able to modify the data file 
via password entry. The investigators will be responsible for the data integrity, and complete data entry 
for each visit as well as the take home questionnaires. The investigator will send the data collected to 
the study sponsor within 5 business days after the last subject completes the final visit. A full report 
will be provided by the investigator at the mutually agreed timeline after the study completion date. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 

Confidential 
EX-MKTG-142 Clinical Evaluation of Proclear Monthly and Avaira Vitality  
19 
 

Confidential 
EX-MKTG-142 Clinical Evaluation of Proclear Monthly and Avaira Vitality  
20